REG - Scancell Holdings - Notice of Results

Scancell HoldingsAnnouncement

22/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260122:nRSV8413Pa&default-theme=true

RNS Number : 8413P  Scancell Holdings Plc  22 January 2026

22 January 2026

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Notice of Interim Results and Investor Presentation

Scancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to
treat cancer, will announce its interim financial results for the six months
ended 31 October 2025 and provide a business update on progress achieved
post-period, on Thursday 29 January 2026.

Phillip L'Huillier, Chief Executive Officer, and Sath Nirmalananthan, Chief
Financial Officer, will host a live webcast for analysts and investors on the
day of the results at 14:00 GMT.

 

If you would like to join the webcast, please follow this link:

 

Interim Financial Results for the six months ending 31 October 2025 |
SparkLive | LSEG
(https://sparklive.lseg.com/ScancellHoldings/events/0e324d6f-4f3a-43b6-8598-82b26bbd6862/interim-financial-results-for-the-six-months-ending-31-october-2025)

 

 

 For further information, please contact:
 Scancell Holdings plc                                         +44 (0) 20 3709 5700
 Phillip L'Huillier, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Panmure Liberum Limited (Nominated Advisor and Joint Broker)  +44 (0) 20 7886 2500
 Emma Earl/ Will Goode, Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                                +44 (0) 20 3705 9330
 David Wilson, Claes Spang

 Investor and media relations
 Mary-Ann Chang                                                +44 (0) 20 7483 284853

                                                               MaryAnnChang@scancell.co.uk

Scancell (LSE:SCLP; www.scancell.co.uk (http://www.scancell.co.uk) ) is a
clinical stage company leveraging two proprietary platforms, Immunobody® and
Moditope®, to develop targeted off-the-shelf, patient-accessible active
immunotherapies designed to generate safe, potent and long-lasting
tumour-specific immunity for a cancer-free future. The lead product, iSCIB1+,
an Immunobody® active immunotherapy that has demonstrated monotherapy
activity in adjuvant melanoma. When combined with checkpoint therapies it
showed additional clinical benefit over the checkpoints (CPI) alone in the
ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient
population that iSCIB1+, in combination with CPIs bring benefit has been
identified - enabling a precision-biomarker led registrational development.
The lead Moditope® peptide active immunotherapy, Modi-1, is being
investigated in a Phase 2 study in a broad range of solid tumours and also has
shown encouraging interim clinical data. Scancell's wholly-owned subsidiary,
Glymab Therapeutics Ltd., is developing an exciting early-stage pipeline of
high affinity GlyMab® antibodies targeting tumour specific glycans, two of
which already have been licensed and are being developed by Genmab A/S, an
international biotechnology company and global leader in the antibody
therapeutics space.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFLFVRLFILFIR



            Copyright 2019 Regulatory News Service, all rights reserved